Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Suspended 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 1Neoplasm Metastasis 1Bulbo-Spinal Atrophy, X-Linked 1Adenocarcinoma 1

Interventions

bicalutamide 5enzalutamide 4exemestane 2darolutamide 2abiraterone 2pembrolizumab 1ostarine 1nilutamide 1cabazitaxel 1apalutamide 1abemaciclib 1Vorinostat 1Triptorelin Pamoate 1Tamoxifen 1Prophylactic Mastectomy 1Prednisolone 1Panobinostat 1Mifepristone 1Letrozole 1Histamine H2 Antagonists 1Histamine Antagonists 1Goserelin 1Doxorubicin 1Docetaxel 1Dasatinib 1Cisplatin 1CP protocol 1Aromatase Inhibitors 1Antiemetics 1Anastrozole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Bulbo-Spinal Atrophy, X-Linked × 5'-ACCaagtttcttcAGC-3' × Clear all
NCT01337518 2012-12-18

A Phase 1a/1b Study to Evaluate the Safety of EZN-4176, in Adult Patients With Castration-Resistant Prostate Cancer

Enzon Pharmaceuticals, Inc.

Phase 1 Suspended
150 enrolled
Genitourinary

Adenocarcinoma, Neoplasm Metastasis, Prostatic Neoplasms, Bulbo-Spinal Atrophy, X-Linked

Data powered by HemOnc (CC BY 4.0) Colophon âš¡